secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2022-02-28T23:59:59+00:00
Accession:  0001171843-22-001448
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q4 net loss $20.1M; CDX-0159 Phase 2 urticaria studies to start Q2 2022
-------------------------------------------------------------------------------

- Net loss of $20.1M ($0.43 diluted EPS) for Q4 2021; full year net loss $70.5M ($1.64 EPS).
- Cash and marketable securities $408.3M as of Dec 31, 2021; provides runway through 2025.
- CDX-0159 Phase 1b CSU data expected July 2022; Phase 2 studies in CSU and CIndU to initiate Q2 2022.
- Plans to expand CDX-0159 development into eosinophilic esophagitis (EoE) with Phase 2 trial in Q4 2022.
- Subcutaneous formulation of CDX-0159 well tolerated; supports planned Phase 2 doses of 75mg, 150mg, 300mg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184322001448/0001171843-22-001448-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184322001448/f8k_022822.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-001448

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer